APPLAUSE-IgAN (2025) — Trial Summary

APPLAUSE-IgAN (2025): This phase 3 trial evaluated iptacopan, an oral factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy, demonstrating the role of complement-mediated kidney injury in IgA nephropathy progression.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.